CHOvolution™ Platform Technology

CHOvolution™ and it's precursor SEFEX are the proprietary, royalty-free host/vector system developed by Celonic. It is a completely serum free, very robust and scaleable system which proved to be able to produce more than 7 g/L of antibodies.

  • Serum-free, suspension adapted CHO-K1 cell line with proven history
  • Regulatory approval in EU, US and Asia
  • Extremely high titers obtained (>7g/l)
  • Very robust and scalable
  • Vector system for expression of protein of interest under control of a strong promoter using random integration with high stringent selection of pools/clones
  • No amplification required

click to read more!


CHOvolution™ based Cell Line Development

Our cell line development provides a safe and highly cost-efficient basis for your project. Our our CHOvolution and it's precursor the SEFEX cell line technology are accepted by various regulatory bodies and provide extremely high titers while being robust and scalable up to large scale production. Each project is unique, so is your cell line. We adapt our cell line development program to the needs of your project to screen and select the best clones for you.

  • CHO K1 based cell line technology
  • Single cell cloning
  • Manufacturability
  • Mock cell line generation
  • Cell line stability studies
  • cGMP cell banking and storage
  • Documentation for IND filing

USP Development

Our USP development team is highly experienced and provides you with robust and cost-efficient processes. We have developed media and know how to adapt and to optimisze them in order to increase expression titer, strengthen cell viability. On average, we double and sometimes more than triple the titer of a developed cell line during the USP development.

  • Media development/optimisation
  • Feeding development/optimisation
  • Optimization of process parameters
  • Shear stress testing
  • 1 L, 10 L and 100L bioreactor systems for non-GMP development and pilot runs

DSP Development

Efficiency is key for a good downstream process : to consistently obtain a pure and high quality product while recovering as much target protein as possible. Celonic has set-up a downstream platform process for antibodies recovering more than 75 % of the target protein. This saves you considerable development time and costs. In addition our experience in process development for non-antibody products enables us to maximize the recovery rate during platform adaptation.      

  • Adaption of State-of-the-art processes for mABs
  • Process development for non-antibody products
  • Process intermediate stability studies
  • Virus clearance studies
  • Extensive experience in purifying products from inhouse CHO cell line